Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 7% – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded down 7% during trading on Thursday . The stock traded as low as $23.25 and last traded at $23.25. 61,856 shares traded hands during trading, a decline of 70% from the average session volume of 205,195 shares. The stock had previously closed at $25.00.

Analyst Ratings Changes

DNTH has been the subject of several recent research reports. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Oppenheimer lifted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Trading Up 1.3 %

The company has a market cap of $704.78 million, a PE ratio of -9.52 and a beta of 1.74. The firm’s fifty day moving average is $26.09 and its 200 day moving average is $26.54.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. As a group, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC boosted its position in shares of Dianthus Therapeutics by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after acquiring an additional 273,670 shares during the last quarter. State Street Corp boosted its position in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Great Point Partners LLC boosted its position in shares of Dianthus Therapeutics by 21.3% during the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after acquiring an additional 132,929 shares during the last quarter. Braidwell LP lifted its position in Dianthus Therapeutics by 34.6% in the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after buying an additional 126,836 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Dianthus Therapeutics by 151.3% in the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after buying an additional 263,500 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.